Marinomed Biotech AG

MARI

ATMARINOMED6

Pharmaceuticals

Delayed Wiener Boerse Other stock markets 05:32:21 2024-05-22 am EDT			5-day change	1st Jan Change
15.3 ^EUR	-6.71%		-8.38%	-47.60%

Apr. 16	Transcript : Marinomed Biotech AG, 2023 Earnings Call, Apr 16, 2024
Apr. 16	Marinomed Biotech AG Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Marinomed Biotech AG Announces Resignation of Karl Lankmayr as Member of the Supervisory Board

October 30, 2020 at 04:00 am EDT

Marinomed Biotech AG has announced that Karl Lankmayr will resign from his post as a member of the supervisory board on 31 October 2020. The company plans to appoint his successor at the next AGM.

Latest news about Marinomed Biotech AG

Transcript : Marinomed Biotech AG, 2023 Earnings Call, Apr 16, 2024	Apr. 16
Marinomed Biotech AG Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 16	CI
Marinomed Biotech Considers Partnerships, Potential Transfer of Carragelose Portfolio	Dec. 18	MT
Marinomed Biotech Signs Deal With DKSH to Commercialize Carragelose in Four Countries	Dec. 14	MT
Transcript : Marinomed Biotech AG, Nine Months 2023 Earnings Call, Nov 21, 2023	Nov. 21
Marinomed Biotech AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 21	CI
Transcript : Marinomed Biotech AG, H1 2023 Earnings Call, Aug 17, 2023	23-08-17
Marinomed Biotech AG Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-17	CI
Marinomed Biotech Enters Technical Cooperation with Chinese Pharmaceutical Group	23-08-09	MT
Austria’s Marinomed Biotech Secures Mexican Market Authorization for Nasal Spray	23-07-27	MT
Marinomed Biotech AG Announces Changes to Its Board	23-06-21	CI
Transcript : Marinomed Biotech AG, Q1 2023 Earnings Call, May 23, 2023	23-05-23
Marinomed Biotech AG Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-23	CI
Transcript : Marinomed Biotech AG, 2022 Earnings Call, Apr 19, 2023	23-04-19
Marinomed Biotech AG Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-19	CI
Austria's Marinomed Biotech Secures US Patent for Solubilization Technology	22-12-27	MT
Marinomed Biotech AG Reports Earnings Results for the Nine Months Ended September 30, 2022	22-11-21	CI
Marinomed Biotech AG Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-25	CI
Marinomed Biotech AG Confirms Financial Outlook for the Fiscal Year 2022	22-08-25	CI
Marinomed Biotech AG Reports Earnings Results for the First Quarter Ended March 31, 2022	22-07-07	CI
Marinomed Biotech AG Announces Management Appointments	22-06-15	CI
Transcript : Marinomed Biotech AG, Q1 2022 Earnings Call, May 23, 2022	22-05-23
Marinomed Biotech AG Confirms Financial Outlook for the Fiscal Year 2022	22-05-23	CI
Marinomed Biotech AG Enters into License Agreement with Proc & Gamble on Carragelose Products	22-05-19	CI
Transcript : Marinomed Biotech AG, 2021 Earnings Call, Apr 13, 2022	22-04-13

Marinomed Biotech AG, formerly known as Marinomed Biotechnologie GmbH is a Austria-based biopharmaceutical company. The company develops antiviral and immunological therapies such as nasal sprays using the respiratory disease antiviral technology platform, Marinosolv and the Carragelose platform. With the Marinosolv technology platform, it is possible to improve the effectiveness of poorly soluble active ingredients. This technology has the potential to change some therapies in the field of allergy and autoimmune diseases. The Carragelose platform is already used in six different products against viral infections of the respiratory tract. The company also offers products for the treatment of influenza, combination products for asthmatics, and others. The company also develops treatments for type I allergies and autoimmune diseases. The company is a spin-off from the University of Veterinary Medicine, Vienna.

Sector

Pharmaceuticals

Calendar

01:45am - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Marinomed Biotech AG

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

16.4 EUR

Average target price

63 EUR

Spread / Average Target

+284.15%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
MARINOMED BIOTECH AG	-47.60%	27.43M
CSL LIMITED	-2.99%	89.49B
SAMSUNG BIOLOGICS CO.,LTD.	+2.50%	40.67B
BIOGEN INC.	-12.01%	33.15B
UCB	+62.42%	26.45B
BIOMARIN PHARMACEUTICAL INC.	-19.79%	14.69B
INCYTE CORPORATION	-8.58%	12.89B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.34%	11.54B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.92%	11.34B
SWEDISH ORPHAN BIOVITRUM AB	+3.90%	8.84B

Biopharmaceuticals